Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288690 · ClinicalTrials.gov registry record · Phase 2
Stress Reduction in Middle Eastern Refugees
A Phase 2 study, sponsored by Wayne State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01288690: Completed Phase 2 study, sponsored by Wayne State University.
NCT01288690 is a Phase 2 study that has completed, run by Wayne State University. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01288690, a Phase 2 study, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This interventional, randomized controlled study tests the effects of a a brief psychological intervention (Narrative Exposure Therapy) against a wait list control group among refugees who have experienced trauma and have some symptoms of PTSD.
Primary Outcome
The number and severity of post traumatic stress disorder symptoms will be assessed using an Arabic adaptation of the Harvard Trauma Questionnaire. The Harvard Trauma Questionnaire will be administered at baseline prior to randomization and 4 months from baseline (about three months from last intervention session). Questions assess symptoms over the preceding one week.
Interventions
- BEHAVIORAL Narrative Exposure Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01288690 record still lists
NCT01288690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which Narrative Exposure Therapy is the first listed.
NCT01288690 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01288690 about?
NCT01288690 is a clinical study titled "Stress Reduction in Middle Eastern Refugees". This interventional, randomized controlled study tests the effects of a a brief psychological intervention (Narrative Exposure Therapy) against a wait list control group among refugees who have experienced trauma and have some symptoms of PTSD.
What is the current status of trial NCT01288690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2010-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01288690?
The interventions under investigation include: Narrative Exposure Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01288690?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01288690's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia